-
摘要: 前列腺癌经传统的雄激素剥夺治疗后, 常转归为去势抵抗性前列腺癌 (castration-resistant prostate cancer, CRPC), 从而影响患者的生活质量。目前, 关于CRPC的治疗是研究热点之一, 本文就细胞毒性化疗药物、新型雄激素受体拮抗剂、免疫治疗、骨转移靶点治疗以及新型分子靶向治疗方面, 对CRPC的治疗研究进行综述, 为临床对患者行个性化治疗提供参考。Abstract: Prostate cancer treated with traditional androgen deprivation therapy often resulted in castration-resistant prostate cancer (CRPC), so the quality of patients' life was affected.The treatments of CRPC become one of the hotspots in current researches.In this paper we summarized the studies about the treatment in the cytotoxic chemotherapy drugs, the novel androgen receptor antagonist, immune therapy, bone transfer therapeutic targets and novel molecular targeted therapy, aiming at providing the reference for the clinical individualized treatment for patients.
-
Key words:
- prostate cancer /
- castration-resistant prostate cancer /
- treatment
-
-
[1] Siegel R L, Miller K D, Jemal A.Cancer statistics, 2015[J].CA Cancer J Clin, 2015, 65 (1):5-29.
[2] 叶定伟, 朱耀.中国前列腺癌的流行病学概述和启示[J].中华外科杂志, 2015, 53 (4):249-252.
[3] Lassi K, Dawson N A.Emerging therapies in castrateresistant prostate cancer[J].Curr Opin Oncol, 2009, 21 (3):260-265.
[4] Tannock I F, Osoba D, Stockler M R, et al.Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer:a Canadian randomized trial with palliative end points[J].J Clin Oncol, 1996, 14 (6):1756-1764.
[5] Petrylak D P.Practical guide to the use of chemotherapy in castration resistant prostate cancer[J].Can JUrol, 2014, 21 (2 Supp 1):77-83.
[6] Tannock I F, de Wit R, Berry W R, et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med, 2004, 351 (15):1502-1512.
[7] de Bono J S, Oudard S, Ozguroglu M, et al.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial[J].Lancet, 2010, 376 (9747):1147-1154.
[8] Suzman D L, Antonarakis E S.Castration-resistant prostate cancer:latest evidence and therapeutic implications[J].Ther Adv Med Oncol, 2014, 6 (4):167-179.
[9] Waltering K K, Urbanucci A, Visakorpi T.Androgen receptor (AR) aberrations in castration-resistant prostate cancer[J].Mol Cell Endocrinol, 2012, 360 (1-2):38-43.
[10] Attard G, Reid A H, A'hern R, et al.Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer[J].J Clin Oncol, 2009, 27 (23):3742-3748.
[11] Ryan C J, Smith M R, de Bono J S, et al.Abiraterone in metastatic prostate cancer without previous chemotherapy[J].N Engl J Med, 2013, 368 (2):138-148.
[12] Tran C, Ouk S, Clegg N J, et al.Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer[J].Science, 2009, 324 (5928):787-790.
[13] Ferlay J, Shin H R, Bray F, et al.Estimates of worldwide burden of cancer in 2008:GLOB-OCAN 2008[J].Int J Cancer, 2010, 127 (12):2893-2917.
[14] Mukherji D, Pezaro C, De-Bono J.MDV3100 for the treatment of prostate cancer[J].Expert Opin Investig Drugs, 2012, 21 (2):227-233.
[15] Scher H I, Beer T M, Higano C S, et al.Antitumour activity of MDV3100 in castration-resistant prostate cancer:aphase 1-2study[J].Lancet, 2010, 375 (9724):1437-1446.
[16] Kantoff P W, Higano C S, Shore N D, et al.SipuleucelT immunotherapy for castration-resistant prostate cancer[J].N Engl J Med, 2010, 363 (5):411-422.
[17] Di LorenzoG, Ferro M, Buonerba C.Sipuleucel-T (Provenge©) for castration-resistant prostate cancer[J].BJUInt, 2012, 110 (2 Pt 2):E99-104.
[18] Drake C G.Update on prostate cancer vaccines[J].Cancer J, 2011, 17 (5):294-299.
[19] Gabrilovich D.Mechanisms and functional significance of tumourinduced dendritic-cell defects[J].Nat Rev Immunol, 2004, 4 (12):941-952.
[20] Gulley J L, Arlen P M, Madan R A, et al.Immunologic and prognostic factors associated with overall survival employing apoxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer[J].Cancer Immunol Immunother, 2010, 59 (5):663-674.
[21] 许标波, 贺毅憬, 王韦力, 等.肿瘤免疫检查点抑制剂临床治疗的研究进展[J].中国临床药理学与治疗学, 2016, 21 (2):218-224.
[22] Gulley J L, Arlen P M, Bastian A, et al.Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer[J].Clin Cancer Res, 2005, 11 (9):3353-3362.
[23] Gerritsen W R, Sharma P.Current and emerging treatment options for castration-resistant prostate cancer:a focus on immunotherapy[J].J Clin Immunol, 2012, 32 (1):25-35.
[24] Tannock I F, de Wit R, Berry W R, et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med, 2004, 351 (15):1502-1512.
[25] Suva L J, Washam C, Nicholas R W, et al.Bone metastasis:mechanisms and therapeutic opportunities[J].Nat Rev Endocrinol, 2011, 7 (4):208-218.
[26] Spencer S, Marini B L, Figg W D.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer[J].Anticancer Res, 2012, 32 (7):2391-2398.
[27] Stopeck A T, Lipton A, Body J J, et al.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, doubleblind study[J].J Clin Oncol, 2010, 28 (35):5132-5139.
[28] Henneman Z J, Nancollas G H, Ebetino F H, et al.Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro[J].J Biomed Mater Res A, 2008, 85 (4):993-1000.
[29] Gnant M, Clézardin P.Direct and indirect anticancer activity of bisphosphonates:a brief review of published literature[J].Cancer Treat Rev, 2012, 38 (5):407-415.
[30] Smith M R, Egerdie B, Hernández Toriz N, et al.Denosumab in men receiving androgen-deprivation therapy for prostate cancer[J].N Eng J Med, 2009, 361 (8):745-755.
[31] Wirth M, Tammela T, Cicalese V, et al.Prevention of bone metastasrs in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid:efficacy and safety results of the zometa European Study (ZEUS) [J].Eur Urol, 2015, 67 (3):482-491.
[32] Morgan C, Lewis P D, Jones R M, et al.The in vitro anti-tumor activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer[J].Acta Oncol, 2007, 46 (5):669-677.
[33] Petersen L J, Lund L, Jonler M, et al.Samarium-153treatment of bone pain in patients with metastatic prostate cancer[J].Dan Med Bull, 2010, 57 (6):A4154.
[34] Finlay I G, Masion M D, Shelley M.Radioisotopes for the palliation of metastatic bone cancer:a systematic review[J].Lancet Oncol, 2005, 6 (6):392-400.
[35] Nilsson S, Larsen R H, Fossa S D, et al.First clinical experience with alpha-emitting radium-233in the treatment of skeletal metastases[J].Clin Cancer Res, 2005, 11 (12):4451-4459.
[36] Hoskin P, Sartor O, O'Sullivan J M, et al.Efficacy and safety of radium-223dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use:a prespecified subgroup analysis from the randomised, double-blind, phase3 ALSYMPCA trial[J].Lancet Oncol, 2014, 15 (12):1397-1406.
[37] Cox H, Hames M, Benrashid M, et al.Radium-223for the Management of Bone Metastases in Castration-Resistant Prostate Cancer[J].J Adv Pract Oncol, 2015, 6 (6):565-570.
[38] Fizazi K, Carducci M, Smith M, et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, doubleblind study[J].Lancet, 2011, 377 (9768):813-822.
[39] Dellis A, Papatsoris A, et al.Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer[J].Expert Rev Pharmacoecon Outcomes Res, 2016, 16 (1):5-10.
[40] 田俊波, 董自强, 曾文, 等.分子靶向治疗在前列腺癌中的研究进展[J].现代生物医学进展, 2015, 15 (10):1984-1986.
-
计量
- 文章访问数: 183
- PDF下载数: 169
- 施引文献: 0
下载: